Last night, OPM announced integration into the LRRK2 Investigative Therapeutics Exchange program from the MJFF, which will allow OPM to contribute to the development of LRRK2-based therapies.Remember that the company is currently seeking a new partner to help advance OPM-201 in the clinic, following successful completion of the Ph1 study end of 2024. In our view, this search could benefit from the Integration in this highly international program.Overall, positive news but without immediate impac ....
